Back to top
more

Azenta (AZTA)

(Delayed Data from NSDQ)

$32.41 USD

32.41
1,038,833

+0.07 (0.22%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $32.36 -0.05 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.

Zacks Equity Research

Azenta (AZTA) Surges 7.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Azenta (AZTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Azenta (AZTA) Q4 Earnings Top Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 63.64% and 0.26%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -129.09% and 0.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Azenta (AZTA) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 128.57% and 4.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.

Zacks Equity Research

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop

by Zacks Equity Research

Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.

Zacks Equity Research

New Strong Buy Stocks for July 16th

by Zacks Equity Research

BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024.

Zacks Equity Research

10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 1,325% and 0.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Shaun Pruitt headshot

3 Stocks to Watch After Impressive Earnings Beats

by Shaun Pruitt

In a somewhat quiet earnings lineup this week, several stocks stand out after posting strong quarterly results on Monday.

Zacks Equity Research

Azenta (AZTA) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 533.33% and 8.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

American Well Corporation (AMWL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

American Well Corporation (AMWL) delivered earnings and revenue surprises of -9.52% and 4.59%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Azenta (AZTA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of -20% and 8.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 16.67% and 6.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pfizer (PFE) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 23% and 7.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down -23.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Brooks (AZTA)

by Zacks Equity Research

Brooks (AZTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Azenta (AZTA) Beats Q1 Earnings Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 100% and 1.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Azenta (AZTA) Q3 Earnings Beat Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?